This page shows the latest drug licensing news and features for those working in and with pharma, biotech and healthcare.
An oral antiviral drug is seen by many as an essential part of an effective medical toolkit against COVID-19. ... Merck has also signed voluntary licensing agreements with five Indian generic drug manufacturers to expand access to molnupiravir, and
Johnson &Johnson (J&J) has pulled out of a $1.6bn licensing deal with Dutch biotech company argenx for the CD70-targeting antibody cusatuzumab. ... In December 2018, J&J and argenx signed a deal centred on cusatuzumab, to develop the drug for the
NGM313 is an antibody targeting the beta-Klotho/FGFR1c receptor complex that could represent a new a completely new drug class for NASH and diabetes. ... The drug works by activating FGFR1c signalling, a pathway that appears to have a key role in
The drug was originally being developed as a treatment for the infectious diseases Ebola and Marbug virus. ... However, despite successfully copying and manufacturing the drug, BrightGene has said it will not launch the drug until it has received
However, Gilead which holds all patents around the development and production of the drug – including for its development as a treatment for coronavirus. ... Although BrightGene has said it has successfully developed and manufactured copies of the drug,
the new one has different ideas on how to pursue studies with this drug”. ... The US biotech had put the LOXL2 drug out for tender as a licensing candidate, and has also already hived off another research programme headed by autotaxin inhibitor PAT-409
More from news
Approximately 2 fully matching, plus 63 partially matching documents found.
Over the past two decades, Alzheimer’s drug discovery has largely focused on targeting the hallmark amyloid protein. ... The most successful projects will validate strong genetic targets and will include licensing opportunities for leading drug target
into drug development costs and approval trends based on data and analyses from multiple proprietary data sets. ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually
Externally, there are the usual issues: downward pressure on hourly rates, reduced client budgets, environmental pressures on new drug development and licensing/reimbursement.
a key licensing agreement and the not inconsequential matter of a management reshuffle. ... Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug
Out licensing WW rights to RN 307 antibody (binds to calcitonin related peptide) phase II ready. ... 18-MC (18-methoxycoronaridine) as a treatment for drug addiction, obesity and compulsive behaviour.
More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.
Prior to this, she has served as senior vice president, head of global business development at Teva Pharmaceuticals, where she led and executed multiple business development transactions ranging from licensing to ... acquisition of drug candidates,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Better patient diversity is critical for clinical trials, in order to develop the right drugs for the right patients, and to support successful drug approvals and effective marketing and communication campaigns. ... Drug licensing and regulatory bodies
The FDA &EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future launch teams and some of the key areas of focus which could make or break a
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...